High plasma levels of soluble ST2 but not its ligand IL-33 is associated with severe forms of pediatric dengue

Cytokine

Volumn 61, Issue 3, 2013, Pages 766-771

  Guerrero, Christian D ^a   Arrieta, Andres F ^a   Ramirez, Nestor D ^a   Rodríguez, Luz Stella ^c   Vega, Rocio ^a,b   Bosch, Irene ^d   Rodríguez, Jairo A ^a,b   Narváez, Carlos F ^a   Salgado, Doris M ^a,b  

^a UNIVERSIDAD SURCOLOMBIANA   (Colombia)

^b Hospital Universitario de Neiva   (Colombia)

^c PONTIFICIA UNIVERSIDAD JAVERIANA   (Colombia)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Dengue; IL 33; Myocarditis; Soluble ST2

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; CREATINE KINASE MB; HEMOGLOBIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR LIKE 1 PROTEIN; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 1BETA; INTERLEUKIN 33; INTERLEUKIN 6; INTERLEUKIN 8; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ARTICLE; BLOOD SAMPLING; CHILD; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENGUE; DISEASE COURSE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEVER; FLOW CYTOMETRY; HEMATOCRIT; HEPATOMEGALY; HUMAN; LETHARGY; MAJOR CLINICAL STUDY; MALE; MUCOSAL BLEEDING; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE COUNT; VIRUS MYOCARDITIS; VOMITING;

ADULT; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DEMOGRAPHY; DENGUE; FEMALE; HUMANS; INTERLEUKIN-6; INTERLEUKIN-8; INTERLEUKINS; LIGANDS; MALE; RECEPTORS, CELL SURFACE; SEVERITY OF ILLNESS INDEX; SOLUBILITY;

EID: 84875381065     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2012.12.024     Document Type: Article

References (50)

1. World Health Organization Dengue guidelines for diagnosis, treatment, prevention and control: new edition 2009, World Health Organization, Geneva.
2. Ranjit S., Kissoon N. Dengue hemorrhagic fever and shock syndromes. Pediatr Crit Care Med 2011, 12:90-100.
3. Suvarna J.C., Rane P.P. Serum lipid profile: a predictor of clinical outcome in dengue infection. Trop Med Int Health: TM & IH 2009, 14:576-585.
4. Mairuhu A.T., Peri G., Setiati T.E., Hack C.E., Koraka P., Soemantri A., et al. Elevated plasma levels of the long pentraxin, pentraxin 3, in severe dengue virus infections. J Med Virol 2005, 76:547-552.
5. Loke P., Hammond S.N., Leung J.M., Kim C.C., Batra S., Rocha C., et al. Gene expression patterns of dengue virus-infected children from nicaragua reveal a distinct signature of increased metabolism. PLoS Neglect Trop Dis 2010, 4:e710.
6. Fink J., Gu F., Ling L., Tolfvenstam T., Olfat F., Chin K.C., et al. Host gene expression profiling of dengue virus infection in cell lines and patients. PLoS Neglect Trop Dis 2007, 1:e86.
7. Ubol S., Masrinoul P., Chaijaruwanich J., Kalayanarooj S., Charoensirisuthikul T., Kasisith J. Differences in global gene expression in peripheral blood mononuclear cells indicate a significant role of the innate responses in progression of dengue fever but not dengue hemorrhagic fever. J Infect Dis 2008, 197:1459-1467.
8. Nascimento E.J., Braga-Neto U., Calzavara-Silva C.E., Gomes A.L., Abath F.G., Brito C.A., et al. Gene expression profiling during early acute febrile stage of dengue infection can predict the disease outcome. PloS One 2009, 4:e7892.
9. Becerra A., Warke R.V., Martin K., Xhaja K., de Bosch N., Rothman A.L., et al. Gene expression profiling of dengue infected human primary cells identifies secreted mediators in vivo. J Med Virol 2009, 81:1403-1411.
10. Hober D., Delannoy A.S., Benyoucef S., De Groote D., Wattre P. High levels of sTNFR p75 and TNF alpha in dengue-infected patients. Microbiol Immunol 1996, 40:569-573.
11. Raghupathy R., Chaturvedi U.C., Al-Sayer H., Elbishbishi E.A., Agarwal R., Nagar R., et al. Elevated levels of IL-8 in dengue hemorrhagic fever. J Med Virol 1998, 56:280-285.
12. Mustafa A.S., Elbishbishi E.A., Agarwal R., Chaturvedi U.C. Elevated levels of interleukin-13 and IL-18 in patients with dengue hemorrhagic fever. FEMS Immunol Med Microbiol 2001, 30:229-233.
13. Spain-Santana T.A., Marglin S., Ennis F.A., Rothman A.L. MIP-1 alpha and MIP-1 beta induction by dengue virus. J Med Virol 2001, 65:324-330.
14. Libraty D.H., Endy T.P., Houng H.S., Green S., Kalayanarooj S., Suntayakorn S., et al. Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections. J Infect Dis 2002, 185:1213-1221.
15. Avila-Aguero M.L., Avila-Aguero C.R., Um S.L., Soriano-Fallas A., Canas-Coto A., Yan S.B. Systemic host inflammatory and coagulation response in the Dengue virus primo-infection. Cytokine 2004, 27:173-179.
16. Lee Y.R., Liu M.T., Lei H.Y., Liu C.C., Wu J.M., Tung Y.C., et al. MCP-1, a highly expressed chemokine in dengue haemorrhagic fever/dengue shock syndrome patients, may cause permeability change, possibly through reduced tight junctions of vascular endothelium cells. J Gen Virol 2006, 87:3623-3630.
17. Butthep P., Chunhakan S., Yoksan S., Tangnararatchakit K., Chuansumrit A. Alteration of cytokines and chemokines during febrile episodes associated with endothelial cell damage and plasma leakage in dengue hemorrhagic Fever. Pediatr Infect Dis J 2012, 31:e232-e238.
18. Becerra A., Warke R.V., de Bosch N., Rothman A.L., Bosch I. Elevated levels of soluble ST2 protein in dengue virus infected patients. Cytokine 2008, 41:114-120.
19. Houghton-Trivino N., Salgado D.M., Rodriguez J.A., Bosch I., Castellanos J.E. Levels of soluble ST2 in serum associated with severity of dengue due to tumour necrosis factor alpha stimulation. J Gen Virol 2010, 91:697-706.
20. Bergers G., Reikerstorfer A., Braselmann S., Graninger P., Busslinger M. Alternative promoter usage of the Fos-responsive gene Fit-1 generates mRNA isoforms coding for either secreted or membrane-bound proteins related to the IL-1 receptor. EMBO J 1994, 13:1176-1188.
21. Tominaga S., Kuroiwa K., Tago K., Iwahana H., Yanagisawa K., Komatsu N. Presence and expression of a novel variant form of ST2 gene product in human leukemic cell line UT-7/GM. Biochem Biophys Res Commun 1999, 264:14-18.
22. Palmer G., Gabay C. Interleukin-33 biology with potential insights into human diseases. Nat Rev Rheumatol 2011, 7:321-329.
23. Kuroiwa K., Arai T., Okazaki H., Minota S., Tominaga S. Identification of human ST2 protein in the sera of patients with autoimmune diseases. Biochem Biophys Res Commun 2001, 284:1104-1108.
24. Brunner M., Krenn C., Roth G., Moser B., Dworschak M., Jensen-Jarolim E., et al. Increased levels of soluble ST2 protein and IgG1 production in patients with sepsis and trauma. Intensive Care Med 2004, 30:1468-1473.
25. Coglianese E.E., Larson M.G., Vasan R.S., Ho J.E., Ghorbani A., McCabe E.L., et al. Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham Heart Study. Clin Chem 2012, 58:1673-1681.
26. Dieplinger B., Januzzi J.L., Steinmair M., Gabriel C., Poelz W., Haltmayer M., et al. Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma - the Presage ST2 assay. Clin Chim Acta 2009, 409:33-40.
27. Wang T.J., Wollert K.C., Larson M.G., Coglianese E., McCabe E.L., Cheng S., et al. Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study. Circulation 2012, 126:1596-1604.
28. Weinberg E.O., Shimpo M., Hurwitz S., Tominaga S., Rouleau J.L., Lee R.T. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 2003, 107:721-726.
29. Shimpo M., Morrow D.A., Weinberg E.O., Sabatine M.S., Murphy S.A., Antman E.M., et al. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation 2004, 109:2186-2190.
30. Weinberg E.O., Shimpo M., De Keulenaer G.W., MacGillivray C., Tominaga S., Solomon S.D., et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation 2002, 106:2961-2966.
31. Braunwald E. Biomarkers in heart failure. New Engl J Med 2008, 358:2148-2159.
32. Nagaratnam N., Siripala K., de Silva N. Arbovirus (dengue type) as a cause of acute myocarditis and pericarditis. Brit Heart J 1973, 35:204-206.
33. Madiyono B., Affandi M. Electrocardiographic evaluation on dengue hemorrhagic fever. Paediatr Indones 1975, 15:161-168.
34. Promphan W., Sopontammarak S., Pruekprasert P., Kajornwattanakul W., Kongpattanayothin A. Dengue myocarditis. Southeast Asian J Trop Med Public Health 2004, 35:611-613.
35. Khongphatthanayothin A., Lertsapcharoen P., Supachokchaiwattana P., La-Orkhun V., Khumtonvong A., Boonlarptaveechoke C., et al. Myocardial depression in dengue hemorrhagic fever: prevalence and clinical description. Pediatr Crit Care Med 2007, 8:524-529.
36. Salgado D., Panqueba C., Vega R., Garzón M., Castro D., Rodriguez J. Mortalidad por dengue hemorrágico en niños en Colombia: más allá del choque. Infectio 2008, 12:247-253.
37. Salgado D.M., Eltit J.M., Mansfield K., Panqueba C., Castro D., Vega M.R., et al. Heart and skeletal muscle are targets of dengue virus infection. Pediatr Infect Dis J 2010.
38. Potts J.A., Gibbons R.V., Rothman A.L., Srikiatkhachorn A., Thomas S.J., Supradish P.O., et al. Prediction of dengue disease severity among pediatric Thai patients using early clinical laboratory indicators. PLoS Neglect Trop Dis 2010, 4:e769.
39. Houghton-Trivino N., Martín K., Giaya K., Rodriguez J.A., Bosch I., Castellanos J.E. Comparación de los perfiles de transcripción de pacientes con fiebre de dengue y fiebre hemorrágica por dengue que muestra diferencias en la respuesta inmunitaria y claves en la inmunopatogénesis. Biomédica 2010, 30:587-597.
40. Braga E.L., Moura P., Pinto L.M., Ignacio S.R., Oliveira M.J., Cordeiro M.T., et al. Detection of circulant tumor necrosis factor-alpha, soluble tumor necrosis factor p75 and interferon-gamma in Brazilian patients with dengue fever and dengue hemorrhagic fever. Mem Inst Oswaldo Cruz 2001, 96:229-232.
41. Azeredo E.L., Zagne S.M., Santiago M.A., Gouvea A.S., Santana A.A., Neves-Souza P.C., et al. Characterisation of lymphocyte response and cytokine patterns in patients with dengue fever. Immunobiology 2001, 204:494-507.
42. Chen L.C., Lei H.Y., Liu C.C., Shiesh S.C., Chen S.H., Liu H.S., et al. Correlation of serum levels of macrophage migration inhibitory factor with disease severity and clinical outcome in dengue patients. Am J Trop Med Hyg 2006, 74:142-147.
43. Basu A., Chaturvedi U.C. Vascular endothelium: the battlefield of dengue viruses. FEMS Immunol Med Microbiol 2008, 53:287-299.
44. Ali S., Huber M., Kollewe C., Bischoff S.C., Falk W., Martin M.U. IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells. Proc Natl Acad Sci USA 2007, 104:18660-18665.
45. Ho L.H., Ohno T., Oboki K., Kajiwara N., Suto H., Iikura M., et al. IL-33 induces IL-13 production by mouse mast cells independently of IgE-FcepsilonRI signals. J Leukocyte Biol 2007, 82:1481-1490.
46. Balato A., Lembo S., Mattii M., Schiattarella M., Marino R., De Paulis A., et al. IL-33 is secreted by psoriatic keratinocytes and induces pro-inflammatory cytokines via keratinocyte and mast cell activation. Exp Dermatol 2012, 21:892-894.
47. Nagata A., Takezako N., Tamemoto H., Ohto-Ozaki H., Ohta S., Tominaga S., et al. Soluble ST2 protein inhibits LPS stimulation on monocyte-derived dendritic cells. Cell Mol Immunol 2012, 9:399-409.
48. Wagenaar J.F., Gasem M.H., Goris M.G., Leeflang M., Hartskeerl R.A., van der Poll T., et al. Soluble ST2 levels are associated with bleeding in patients with severe Leptospirosis. PLoS Neglect Trop Diseases 2009, 3:e453.
49. Sanada S., Hakuno D., Higgins L.J., Schreiter E.R., McKenzie A.N., Lee R.T. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest 2007, 117:1538-1549.
50. Seki K., Sanada S., Kudinova A.Y., Steinhauser M.L., Handa V., Gannon J., et al. Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. Circ Heart Fail 2009, 2:684-691.